Gilead Sciences
GILD
Market cap $136B

109.64 USD

-4.90

4.28%

At close Jul 11, 4:00 PM EDT

After hours

109.50

-0.14

0.13%

1 day

-4.28%

5 days

-2.11%

1 month

0.31%

3 months

5.80%

6 months

21.90%

Year to date

19.33%

1 year

56.70%

5 years

42.98%

10 years

-4.29%

About: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).

Employees: 17,600

Healthcare Drug Manufacturers - General

0

Funds holding %

of 7,312 funds

0

Analysts bullish %

of 5 analysts

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

149% more first-time investments, than exits

New positions opened: 276 | Existing positions closed: 111

79% more funds holding in top 10

Funds holding in top 10: 28 [Q4 2024] → 50 (+22) [Q1 2025]

19% more capital invested

Capital invested by funds: $98.3B [Q4 2024] → $117B (+$18.3B) [Q1 2025]

6% more funds holding

Funds holding: 1,852 [Q4 2024] → 1,970 (+118) [Q1 2025]

0% more call options, than puts

Call options by funds: $1.2B | Put options by funds: $1.19B

1.62% less ownership

Funds ownership: 85.16% [Q4 2024] → 83.55% (-1.62%) [Q1 2025]

16% less repeat investments, than reductions

Existing positions increased: 674 | Existing positions reduced: 807

See Fund Rankings

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$117

7%

upside

Avg. target

$124

13%

upside

High target

$135

23%

upside

5 analyst ratings

5 positive

100%

0 neutral

0%

0 negative

0%

Mizuho Salim Syed	7%upside $117	Outperform Maintained	5 May 2025
Oppenheimer Hartaj Singh	14%upside $125	Outperform Maintained	25 Apr 2025
Morgan Stanley Matthew Harrison	23%upside $135	Overweight Maintained	25 Apr 2025
Cantor Fitzgerald Carter Gould	14%upside $125	Overweight Assumed	22 Apr 2025
BMO Capital Evan Seigerman	9%upside $120	Outperform Maintained	17 Apr 2025

See Analyst Rankings

Financial journalist opinion

Based on 61 articles about GILD published over the past 30 days

Zacks Investment Research

Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Here's Why Gilead Sciences (GILD) is a Strong Momentum Stock

Zacks Investment Research

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

In the most recent trading session, Gilead Sciences (GILD) closed at $113.24, indicating a +1.96% shift from the previous trading day.

Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know

AHF: Gilead's Greed Costs Latin America HIV Protection

MEXICO CITY--(BUSINESS WIRE)--AIDS Healthcare Foundation (AHF) denounces Gilead Sciences for once again excluding Latin America and the Caribbean (LAC) from affordable access to a groundbreaking HIV prevention drug, lenacapavir. Today's announcement of a pricing and procurement deal between Gilead and the Global Fund to Fight AIDS, Tuberculosis and Malaria leaves most countries in the region out, forcing them to negotiate individually and in secrecy. “Once again, Latin America and the Caribbean.

AHF: Gilead's Greed Costs Latin America HIV Protection

Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million

Gilead Sciences, Inc. GILD on Wednesday announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria to supply lenacapavir — Gilead's twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-exposure prophylaxis (PrEP).

Gilead's Lenacapavir Plan Faces Global Hurdles As It Commits To No-Profit Access for 2 Million

Zacks Investment Research

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term

Zacks Investment Research

Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet

When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?

Brokers Suggest Investing in Gilead (GILD): Read This Before Placing a Bet

Gilead, Global Fund finalize plan to supply HIV prevention drug to poor countries

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the absence of funding from a key U.S. initiative aimed at addressing the global HIV/AIDS epidemic.

Gilead, Global Fund finalize plan to supply HIV prevention drug to poor countries

Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced a strategic partnership agreement with the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to supply lenacapavir—Gilead's twice-yearly injectable HIV-1 capsid inhibitor—for the prevention of HIV as pre-exposure prophylaxis (PrEP). Through the agreement, Gilead will supply enough doses to reach up to two million people over three years in countries supported by the Global Fund, at no prof.

Gilead Finalizes Agreement With the Global Fund to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention for up to Two Million People in Primarily Low- and Lower-Middle-Income Countries

CNBC Television

Final Trades: Synovus, Nextera Energy, Gilead and the IYF

The Investment Committee give you their top stocks to watch for the second half.

Final Trades: Synovus, Nextera Energy, Gilead and the IYF

Zacks Investment Research

Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

GILD jumps 27.2% in six months as FDA nod for twice-yearly HIV drug Yeztugo boosts its HIV franchise and growth outlook.

Gilead Sciences Rallies 27.2% in Six Months: Buy or Sell the Stock?

See News Rankings

Charts implemented using Lightweight Charts™